The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...
Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...
ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...
"This technology could be important for in vivo delivery," meaning ... The COVID-19 vaccines manufactured by Pfizer-BioNTech ...
The mRNA vaccines developed to fight COVID-19 during the pandemic "did have a very important impact in decreasing hospitalizations, severe pneumonia and death." ...
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers ...
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025. The ...
Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing ...
FRIDAY, Oct. 24, 2025 (HealthDay News) — The mRNA technology powering some COVID vaccines may hold a surprising benefit for ...
Research indicates that COVID-19 mRNA vaccines, initially developed to combat the pandemic, could significantly enhance cancer immunotherapy outcomes. Patients receiving these vaccines alongside ...
The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback